Lomond Therapeutics

Lomond Therapeutics is a biopharmaceutical company co-founded by OrbiMed, Torrey Pines Investment, and Dr. John C. Byrd, focusing on the discovery and development of best-in-class and first-in-class small molecule inhibitors targeting escape mutations in hematologic cancers. The company leverages Expert Systems Inc.'s proprietary hybrid AI platform, utilizing proprietary data, chembio platforms, knowledge, and expertise from its key partners to select highly valuable pathological molecular mechanisms; precisely design and accelerate the execution of discovering and developing best-in-class and first-in-class therapies. Lomond Therapeutics aims to utilize its capabilities and platform to become a leader in the development of novel breakthrough drugs, maximizing the clinical benefits for treating hematologic malignancies.